QTRX vs. EYPT, PACB, LAB, CTKB, NAUT, DH, LYEL, AUNA, MLYS, and PHAR
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Standard BioTools (LAB), Cytek Biosciences (CTKB), Nautilus Biotechnology (NAUT), Definitive Healthcare (DH), Lyell Immunopharma (LYEL), Auna (AUNA), Mineralys Therapeutics (MLYS), and Pharming Group (PHAR). These companies are all part of the "medical" sector.
Quanterix (NASDAQ:QTRX) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
In the previous week, EyePoint Pharmaceuticals had 17 more articles in the media than Quanterix. MarketBeat recorded 23 mentions for EyePoint Pharmaceuticals and 6 mentions for Quanterix. Quanterix's average media sentiment score of 1.01 beat EyePoint Pharmaceuticals' score of 0.27 indicating that Quanterix is being referred to more favorably in the media.
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 6.9% of Quanterix shares are owned by company insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Quanterix has a net margin of -28.82% compared to EyePoint Pharmaceuticals' net margin of -157.77%. Quanterix's return on equity of -10.39% beat EyePoint Pharmaceuticals' return on equity.
Quanterix has higher revenue and earnings than EyePoint Pharmaceuticals. Quanterix is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Quanterix currently has a consensus price target of $30.60, indicating a potential upside of 74.86%. EyePoint Pharmaceuticals has a consensus price target of $33.71, indicating a potential upside of 183.55%. Given EyePoint Pharmaceuticals' higher probable upside, analysts plainly believe EyePoint Pharmaceuticals is more favorable than Quanterix.
Quanterix has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
EyePoint Pharmaceuticals received 184 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 69.81% of users gave EyePoint Pharmaceuticals an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Summary
Quanterix beats EyePoint Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
